Cellular interactions in self-directed immune-mediated liver diseases

IF 33 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Journal of Hepatology Pub Date : 2025-01-08 DOI:10.1016/j.jhep.2025.01.002
Amber G. Bozward , Scott P. Davies , Sean M. Morris , Kayani Kayani , Ye H. Oo
{"title":"Cellular interactions in self-directed immune-mediated liver diseases","authors":"Amber G. Bozward ,&nbsp;Scott P. Davies ,&nbsp;Sean M. Morris ,&nbsp;Kayani Kayani ,&nbsp;Ye H. Oo","doi":"10.1016/j.jhep.2025.01.002","DOIUrl":null,"url":null,"abstract":"<div><div>The lymphocyte population must traverse a complex path throughout their journey to the liver. The signals which these cells must detect, including cytokines, chemokines and other soluble factors, steer their course towards further crosstalk with other hepatic immune cells, hepatocytes and biliary epithelial cells. A series of specific chemokine receptors and adhesion molecules drive not only the recruitment, migration, and retention of these cells within the liver, but also their localisation. Perturbation of these interactions and failure of self-recognition drive the development of several autoimmune liver diseases. We also describe check point-induced liver injury. Immune cell internalisation into hepatocytes (emperipolesis) in autoimmune hepatitis and into biliary epithelial cells (intra-epithelial lymphocyte) in primary biliary cholangitis are typical features in autoimmune liver diseases. Finally, we describe emerging immune-based therapies, including regulatory T cell, anti-cytokine and anti-chemokine therapies, cytokine supplementation (<em>e.g.</em> interleukin-2), as well as co-inhibitory molecule manipulation, including T-cell engagers, and discuss their potential application in the treatment of autoimmune liver diseases.</div></div>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 6","pages":"Pages 1110-1124"},"PeriodicalIF":33.0000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168827825000066","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The lymphocyte population must traverse a complex path throughout their journey to the liver. The signals which these cells must detect, including cytokines, chemokines and other soluble factors, steer their course towards further crosstalk with other hepatic immune cells, hepatocytes and biliary epithelial cells. A series of specific chemokine receptors and adhesion molecules drive not only the recruitment, migration, and retention of these cells within the liver, but also their localisation. Perturbation of these interactions and failure of self-recognition drive the development of several autoimmune liver diseases. We also describe check point-induced liver injury. Immune cell internalisation into hepatocytes (emperipolesis) in autoimmune hepatitis and into biliary epithelial cells (intra-epithelial lymphocyte) in primary biliary cholangitis are typical features in autoimmune liver diseases. Finally, we describe emerging immune-based therapies, including regulatory T cell, anti-cytokine and anti-chemokine therapies, cytokine supplementation (e.g. interleukin-2), as well as co-inhibitory molecule manipulation, including T-cell engagers, and discuss their potential application in the treatment of autoimmune liver diseases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
自我导向免疫介导的肝脏疾病中的细胞相互作用
淋巴细胞群在到达肝脏的过程中必须经过一条复杂的路径。这些细胞必须检测到的信号,包括细胞因子、趋化因子和其他可溶性因子,引导它们与其他肝免疫细胞、肝细胞和胆道上皮细胞进一步串扰。一系列特定的趋化因子受体和粘附分子不仅驱动这些细胞在肝脏内的募集、迁移和保留,而且还驱动它们的定位。这些相互作用的扰动和自我识别的失败驱动了几种自身免疫性肝病的发展。了解这些相互作用的本质有助于我们对免疫介导的肝脏疾病发病机制的理解,为解决不受控制的炎症提供新的干预机会。在这篇综述中,我们提供了复杂的募集途径和细胞相互作用的肝脏定位淋巴细胞群的概述。我们讨论了这些通路在自身免疫性疾病中是如何被破坏的,并强调了自身免疫性肝炎中肝细胞内的免疫细胞(emperipolesis)和原发性胆道胆管炎中胆道上皮细胞内的免疫细胞(上皮内淋巴细胞)的机制,以及操纵这些通路进行治疗的途径。我们还涵盖了免疫介导的组织损伤机制受检查点抑制剂的影响,导致检查点抑制剂诱导的肝损伤(CHILI)。最后,我们描述了新兴的基于免疫的疗法,包括调节性T细胞,抗细胞因子和抗趋化因子疗法,细胞因子补充,如白细胞介素-2,以及许多共同抑制分子操作的模式,包括双特异性T细胞参与(BiTEs)和检查点抑制剂双特异性T细胞参与(CiTEs),并讨论了它们在自身免疫性肝病治疗中的潜在应用。免疫介导的肝病包括两大类:自身免疫性和炎症性肝损伤,前者是由免疫自身耐受性的破坏引起的。这些具有共同特征,即组织学上致密的免疫浸润,自身抗体阳性和免疫球蛋白升高。虽然在其流行病学、表现和诊断评价方面有很好的定义,但其治疗仍然是一个未满足的临床需求。我们对导致免疫自我耐受性崩溃的机制的不完全理解和我们无法恢复免疫稳态阻碍了目前治疗的进展。本文综述了肝脏耐受性丧失及其细胞相互作用的最新进展,包括免疫细胞对肝细胞和胆道上皮细胞的侵袭,检查点诱导的免疫介导的肝损伤(CHILI),并总结了目前治疗策略的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Hepatology
Journal of Hepatology 医学-胃肠肝病学
CiteScore
46.10
自引率
4.30%
发文量
2325
审稿时长
30 days
期刊介绍: The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
期刊最新文献
Utilization of liver grafts obtained from donation after medical assistance in dying: A Canadian multicenter experience. Addressing the Risk of HBV Transmission in Serodifferent Partners Recurrence pattern for HBV-related HCC after liver transplantation in the antiviral era Viral infection as a trigger for primary sclerosing cholangitis in genetically susceptible individuals Associations of accelerated biological aging with steatotic liver disease and fibrosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1